DOCSLIB.ORG

Evidence That Human Β-Cells Process Proinsulin with Prohormone Convertase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evidence That Human Β-Cells Process Proinsulin with Prohormone Convertase Diabetes Volume 69, July 2020 1451 Revisiting Proinsulin Processing: Evidence That Human b-Cells Process Proinsulin With Prohormone Convertase (PC) 1/3 but Not PC2 Adam Ramzy,1 Ali Asadi,1 and Timothy J. Kieffer1,2 Diabetes 2020;69:1451–1462 | https://doi.org/10.2337/db19-0276 Insulin is first produced in pancreatic b-cells as the B-chain and COOH-terminal A-chain with a connecting precursor prohormone proinsulin. Defective proinsulin C-peptide, many studies have attempted to clarify how processing has been implicated in the pathogenesis of b-cells excise the C-peptide to liberate mature insulin. both type 1 and type 2 diabetes. Though there is sub- Current theory posits that the B-chain–C-peptide junction stantial evidence that mouse b-cells process proinsulin is cleaved by prohormone convertase 1/3 (PC1/3; gene using prohormone convertase 1/3 (PC1/3) and then pro- PCSK1) before cleavage at the C-peptide–A-chain junction fi hormone convertase 2 (PC2), this nding has not been by prohormone convertase 2 (PC2; gene PCSK2). PC2 fi b fl veri ed in human -cells. Immuno uorescence with val- knockout mice have impaired processing at the C-A ISLET STUDIES idated antibodies revealed that there was no detectable junction, resulting in a buildup of des-31,32 proinsulin (2), PC2 immunoreactivity in human b-cells and little PCSK2 and PC1/3 knockout mice have severely impaired process- mRNA by in situ hybridization. Similarly, rat b-cells were ing at the B-C junction, resulting in a buildup of des-64,65 not immunoreactive for PC2. In all histological experi- proinsulin (3). Based on relative processing rates of intact ments, PC2 immunoreactivity in neighboring a-cells acted as a positive control. In donors with type 2 diabe- human proinsulin versus des-31,32 proinsulin or des-64,65 tes, b-cells had elevated PC2 immunoreactivity, sug- proinsulin by rat PC1/3 and PC2, processing at the B-C gesting that aberrant PC2 expression may contribute junction by PC1/3 likely occurs before processing by PC2 at to impaired proinsulin processing in b-cells of patients the C-A junction (4), but some data have countered this with diabetes. To support histological findings using hypothesis by showing more buildup of des-64,65 proinsu- a biochemical approach, human islets were used lin during the processing of rat insulin 2 in islets (5). for pulse-chase experiments. Despite inhibition of PC2 While past work supports the theory that primary function by temperature blockade, brefeldin A, chloro- mouse b-cells process proinsulin sequentially by PC1/3 quine, and multiple inhibitors that blocked production of and then PC2, there is some indication that PC2 may not mature glucagon from proglucagon, b-cells retained the be as important in human b-cells as it is in mouse b-cells. ability to produce mature insulin. Conversely, suppression Humans with mutant PCSK1 have circulating hyperproin- of PC1/3 blocked processing of proinsulin but not proglu- sulinemia (6), but there are no associations between PCSK2 cagon. By demonstrating that healthy human b-cells pro- polymorphisms and circulating proinsulin (7). Though cess proinsulin by PC1/3 but not PC2, we suggest that a human b-cell line (EndoC-bH2) has abundant PCSK1 and there is a need to revise the long-standing theory of pro- PCSK2 (8), RNA-sequencing experiments on sorted pri- insulin processing. mary a-cells and b-cells indicate higher expression of PCSK2 than PCSK1 in mouse b-cells (9), whereas human In 1967, Steiner et al. (1) demonstrated with pulse-chase b-cells expressed ;20 times more PCSK1 than PCSK2 (10) experiments that insulin is generated from a larger pre- (Supplementary Fig. 1). Additionally, Davalli et al. (11) cursor they named “proinsulin.” After the general structure reported a deficiency of immunoreactive PC2 in human islet fi b of insulin was identi ed as containing an NH2-terminal -cells transplanted into mice and some human insulinomas 1Laboratory of Molecular and Cellular Medicine, Department of Cellular and This article contains supplementary material online at https://doi.org/10.2337/ Physiological Sciences, Life Sciences Institute, The University of British Columbia, db20-4567/suppl.12074721. Vancouver, British Columbia, Canada © 2020 by the American Diabetes Association. Readers may use this article as 2 Department of Surgery, The University of British Columbia, Vancouver, British long as the work is properly cited, the use is educational and not for profit, and the Columbia, Canada work is not altered. More information is available at https://www.diabetesjournals Corresponding author: Timothy J. Kieffer, [email protected] .org/content/license. Received 13 March 2019 and accepted 3 April 2020 1452 Human b-Cells Process Proinsulin With PC1/3 Diabetes Volume 69, July 2020 are not immunoreactive for PC2 (12). Collectively, there is no Immunohistofluorescence definitive evidence that proinsulin is processed by both PC1/3 Immunofluorescent staining was performed as previously and PC2 in human b-cells,andthereissomeindicationthat described (21). Briefly, sections were deparaffinized in PC2, while critical for proglucagon processing in a-cells xylene (three times for 5 min) and rehydrated in graded (13), is not abundantly expressed in human b-cells. ethanol (100%, two times for 5 min, 95% for 5 min, 70% In this study, we use validated antibodies and oligonu- for 5 min, and PBS for 10 min) before heat-induced epitope cleotide probes to determine that primary human b-cells retrieval in an EZ-Retriever microwave oven (BioGenex, Fre- have no detectable PC2 and little detectable PCSK2.We mont, CA) for 15 min at 95°C in 10 mmol/L citrate buffer also performed pulse-chase experiments and suppressed (0.5% Tween 20, pH 6.0) (Thermo Fisher Scientific, Waltham, the function of PC2 by temperature blockade (14), bre- MA). Samples were blocked in Dako Protein Block, Serum Free feldin A (15,16), the weak base chloroquine (14), and (Dako Canada, Burlington, Ontario Canada), and incubated multiple inhibitors (17,18). In the absence of full PC2 overnight in primary antibody diluted in Dako Antibody function, human b-cells can produce mature insulin, but Diluent. The following day, slides were washed and incubated neighboring a-cells produce little mature glucagon. in secondary antibody (Alexa Fluor–conjugated secondary Moreover, we provide evidence that PC1/3 is responsible antibodies; Life Technologies) for 1 h at room temperature for processing human proinsulin by inhibiting the function before mounting and counterstaining with VECTASHIELD of PC1/3 using two inhibitors (18,19) to impair formation HardSet Mounting Medium with nuclear stain DAPI (Vector of mature insulin with no significant effect on proglucagon Laboratories, Burlingame, CA). All images were captured processing. These findings provide a more advanced un- and analyzed with an ImageXpress Micro XLS System derstanding of the processing of proinsulin and suggest the (Molecular Devices, LLC, San Jose, CA) with a scientific need to reconsider the widely accepted thought that human CMOS camera, a Nikon 20X Plan Apo objective (numer- proinsulin is processed sequentially by PC1/3 and then PC2. ical aperture of 0.75, 1-6300-0196; Nikon, Tokyo, Japan), Our findings suggest that in human b-cells, PC1/3 is re- and DAPI (DAPI-5060B), FITC (FITC-3540B), Cy3 (Cy3– sponsible for processing human proinsulin without PC2. 4040B), Texas Red (TXRED-4040B), and Cy5 (Cy5– 4040A) filter cubes. Image analysis was performed on RESEARCH DESIGN AND METHODS MetaXpress software (version 6.2.3.733; Molecular Devi- Experimental Models and Subject Details ces, LLC). HumanpancreastissuebiopsieswerecollectedbytheIke Barber Human Islet Transplant Laboratory (Vancouver, British Cell Sorting Columbia, Canada). Human pancreas tissue biopsies and A total of 10,000–20,000 human islet equivalents were cadaveric human islets were provided by the Alberta Diabetes dispersed in 0.05% trypsin before magnetic bead purifica- Institute IsletCore (Edmonton, Alberta, Canada) after isolation tion according to a published protocol (22). by standardized protocol (20). Sample collection and islet Western Blotting isolation were approved by the Human Research Ethics Board Groups of 250 mouse islets, 1,000 human islet equivalents, at the University of Alberta (Pro00013094). All donors’ fam- or ;1 million EndoC-bH1 cells were lysed in 200 mL lysis ilies gave informed consent for the use of pancreatic tissue in buffer (50 mmol/L Tris, pH 8.0, 150 mmol/L NaCl, 0.02% research, and all work with human tissues was approved by the Na azide, 0.1% SDS, 1% Nonidet P-40, 0.5% sodium Research Ethics Board (H14-02949), The University of British deoxycholate, 1 mmol/L phenylmethyl sulfonyl fluoride, Columbia (Vancouver, British Columbia, Canada). Basic donor and protease inhibitor cocktail [Sigma-Aldrich, St. Louis, demographics are detailed in Supplementary Tables 2 and 3. MO]) as per a published protocol (15). Levels of proteins of All experiments with animals were approved by the University interest were assessed by fluorescent Western blotting of British Columbia Animal Care Committee and carried out methods using two PC2 antibodies (1:1,000, MAB6018, in accordance with the Canadian Council on Animal Care R&D Systems; and 1:1,000, PA5-14594, Thermo Fisher Guidelines. Scientific), anti-PC1/3 antibody (1:2,500; gift from Lakshmi Devi), and an anti–a-tubulin antibody (1:1,000; Sigma- Paraffin-Embedded Samples Aldrich) and detected on a LI-COR Odyssey 9120 Imaging C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) system (LI-COR Biosciences, Lincoln, NE). were sacrificed at 12 weeks of age. Following euthanasia, the pancreas was quickly dissected out of mice, washed in PBS, and In Situ Hybridization fixed in 4% paraformaldehyde overnight before being trans- For all in situ hybridization experiments, we used tissue ferred to 70% ethanol for storage prior to paraffin embedding samples collected and sectioned in all RNase-free solu- and sectioning (5-mm thickness) (Wax-it Histology Services tions (including paraformaldehyde, 70% ethanol, and Inc., Vancouver, British Columbia, Canada).
Load more

Recommended publications
  • Resolving Transcriptional States and Predicting Lineages in the Annelid Capitella Teleta Using 1 Single-Cell Rnaseq 2 3 Abhinav
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342709; this version posted October 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Resolving transcriptional states and predicting lineages in the annelid Capitella teleta using 2 single-cell RNAseq 3 4 Abhinav Sur1 and Néva P. Meyer2* 5 6 1Unit on Cell Specification and Differentiation, National Institute of Child Health and Human 7 Development (NICHD), Bethesda, Maryland, USA, 20814 8 9 2Department of Biology, Clark University, 950 Main Street, Worcester, Massachusetts, USA, 10 01610. 11 12 13 [email protected] 14 [email protected] 15 16 *Corresponding author 17 18 19 20 21 Keywords: neurogenesis, single-cell RNAseq, annelid, cell type, differentiation trajectory, 22 pseudotime, RNA velocity, gene regulatory network. 23 bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342709; this version posted October 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 24 Abstract 25 Evolution and diversification of cell types has contributed to animal evolution. However, gene 26 regulatory mechanisms underlying cell fate acquisition during development remains largely 27 uncharacterized in spiralians. Here we use a whole-organism, single-cell transcriptomic approach 28 to map larval cell types in the annelid Capitella teleta at 24- and 48-hours post gastrulation 29 (stages 4 and 5).
    [Show full text]
  • Downloaded from the National Database for Autism Research (NDAR)
    International Journal of Molecular Sciences Article Phenotypic Subtyping and Re-Analysis of Existing Methylation Data from Autistic Probands in Simplex Families Reveal ASD Subtype-Associated Differentially Methylated Genes and Biological Functions Elizabeth C. Lee y and Valerie W. Hu * Department of Biochemistry and Molecular Medicine, The George Washington University, School of Medicine and Health Sciences, Washington, DC 20037, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-202-994-8431 Current address: W. Harry Feinstone Department of Molecular Microbiology and Immunology, y Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. Received: 25 August 2020; Accepted: 17 September 2020; Published: 19 September 2020 Abstract: Autism spectrum disorder (ASD) describes a group of neurodevelopmental disorders with core deficits in social communication and manifestation of restricted, repetitive, and stereotyped behaviors. Despite the core symptomatology, ASD is extremely heterogeneous with respect to the severity of symptoms and behaviors. This heterogeneity presents an inherent challenge to all large-scale genome-wide omics analyses. In the present study, we address this heterogeneity by stratifying ASD probands from simplex families according to the severity of behavioral scores on the Autism Diagnostic Interview-Revised diagnostic instrument, followed by re-analysis of existing DNA methylation data from individuals in three ASD subphenotypes in comparison to that of their respective unaffected siblings. We demonstrate that subphenotyping of cases enables the identification of over 1.6 times the number of statistically significant differentially methylated regions (DMR) and DMR-associated genes (DAGs) between cases and controls, compared to that identified when all cases are combined. Our analyses also reveal ASD-related neurological functions and comorbidities that are enriched among DAGs in each phenotypic subgroup but not in the combined case group.
    [Show full text]
  • Type 1 Diabetes Autoantigen Epitope in the Pathogenesis of Junction of Proinsulin Is an Early Evidence That a Peptide Spanning T
    Evidence That a Peptide Spanning the B-C Junction of Proinsulin Is an Early Autoantigen Epitope in the Pathogenesis of Type 1 Diabetes This information is current as of September 24, 2021. Wei Chen, Isabelle Bergerot, John F. Elliott, Leonard C. Harrison, Norio Abiru, George S. Eisenbarth and Terry L. Delovitch J Immunol 2001; 167:4926-4935; ; doi: 10.4049/jimmunol.167.9.4926 Downloaded from http://www.jimmunol.org/content/167/9/4926 References This article cites 50 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/167/9/4926.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 24, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Evidence That a Peptide Spanning the B-C Junction of Proinsulin Is an Early Autoantigen Epitope in the Pathogenesis of Type 1 Diabetes1 Wei Chen,2* Isabelle Bergerot,2* John F.
    [Show full text]
  • Sulfatide Preserves Insulin Crystals Not by Being Integrated in the Lattice but by Stabilizing Their Surface
    Hindawi Publishing Corporation Journal of Diabetes Research Volume 2016, Article ID 6179635, 4 pages http://dx.doi.org/10.1155/2016/6179635 Research Article Sulfatide Preserves Insulin Crystals Not by Being Integrated in the Lattice but by Stabilizing Their Surface Karsten Buschard,1 Austin W. Bracey,2 Daniel L. McElroy,2 Andrew T. Magis,2 Thomas Osterbye,1 Mark A. Atkinson,2 Kate M. Bailey,2 Amanda L. Posgai,2 and David A. Ostrov2 1 Bartholin Instituttet, Rigshospitalet, 2100 Copenhagen, Denmark 2Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, 1600 SW Archer Road, Gainesville, FL 32610, USA Correspondence should be addressed to Karsten Buschard; [email protected] Received 30 October 2015; Revised 14 January 2016; Accepted 14 January 2016 Academic Editor: Fabrizio Barbetti Copyright © 2016 Karsten Buschard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Sulfatide is known to chaperone insulin crystallization within the pancreatic beta cell, but it is not known if this results from sulfatide being integrated inside the crystal structure or by binding the surface of the crystal. With this study, we aimed to characterize the molecular mechanisms underlying the integral role for sulfatide in stabilizing insulin crystals prior to exocytosis. Methods. We cocrystallized human insulin in the presence of sulfatide and solved the structure by molecular replacement. Results. The crystal structure of insulin crystallized in the presence of sulfatide does not reveal ordered occupancy representing sulfatide in the crystal lattice, suggesting that sulfatide does not permeate the crystal lattice but exerts its stabilizing effect by alternative interactions such as on the external surface of insulin crystals.
    [Show full text]
  • Isolation and Proteomics of the Insulin Secretory Granule
    H OH metabolites OH Review Isolation and Proteomics of the Insulin Secretory Granule Nicholas Norris , Belinda Yau * and Melkam Alamerew Kebede Charles Perkins Centre, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia; [email protected] (N.N.); [email protected] (M.A.K.) * Correspondence: [email protected] Abstract: Insulin, a vital hormone for glucose homeostasis is produced by pancreatic beta-cells and when secreted, stimulates the uptake and storage of glucose from the blood. In the pancreas, insulin is stored in vesicles termed insulin secretory granules (ISGs). In Type 2 diabetes (T2D), defects in insulin action results in peripheral insulin resistance and beta-cell compensation, ultimately leading to dysfunctional ISG production and secretion. ISGs are functionally dynamic and many proteins present either on the membrane or in the lumen of the ISG may modulate and affect different stages of ISG trafficking and secretion. Previously, studies have identified few ISG proteins and more recently, proteomics analyses of purified ISGs have uncovered potential novel ISG proteins. This review summarizes the proteins identified in the current ISG proteomes from rat insulinoma INS-1 and INS-1E cell lines. Here, we also discuss techniques of ISG isolation and purification, its challenges and potential future directions. Keywords: insulin secretory granule; beta-cells; granule protein purification 1. Insulin Granule Biogenesis and Function Citation: Norris, N.; Yau, B.; Kebede, The insulin secretory granule (ISG) is the storage vesicle for insulin in pancreatic M.A. Isolation and Proteomics of the beta-cells. It was long treated as an inert carrier for insulin but is now appreciated as a Insulin Secretory Granule.
    [Show full text]
  • Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes
    258 Diabetes Care Volume 42, February 2019 Proinsulin Secretion Is a Emily K. Sims,1,2 Henry T. Bahnson,3 Julius Nyalwidhe,4 Leena Haataja,5 Persistent Feature of Type 1 Asa K. Davis,3 Cate Speake,3 Linda A. DiMeglio,1,2 Janice Blum,6 Diabetes Margaret A. Morris,7 Raghavendra G. Mirmira,1,2,8,9,10 7 10,11 Diabetes Care 2019;42:258–264 | https://doi.org/10.2337/dc17-2625 Jerry Nadler, Teresa L. Mastracci, Santica Marcovina,12 Wei-Jun Qian,13 Lian Yi,13 Adam C. Swensen,13 Michele Yip-Schneider,14 C. Max Schmidt,14 Robert V. Considine,9 Peter Arvan,5 Carla J. Greenbaum,3 Carmella Evans-Molina,2,8,9,10,15 and the T1D Exchange Residual C-peptide Study Group* OBJECTIVE Abnormally elevated proinsulin secretion has been reported in type 2 and early type 1 diabetes when significant C-peptide is present. We questioned whether individuals with long-standing type 1 diabetes and low or absent C-peptide secretory capacity retained the ability to make proinsulin. RESEARCH DESIGN AND METHODS C-peptide and proinsulin were measured in fasting and stimulated sera from 319 subjects with long-standing type 1 diabetes (‡3 years) and 12 control subjects without diabetes. We considered three categories of stimulated C-peptide: 1) 1Department of Pediatrics, Indiana University ‡ 2 School of Medicine, Indianapolis, IN C-peptide positive, with high stimulated values 0.2 nmol/L; ) C-peptide posi- 2 tive, with low stimulated values ‡0.017 but <0.2 nmol/L; and 3)C-peptide Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indian- <0.017 nmol/L.
    [Show full text]
  • Identification of Potential Key Genes and Pathway Linked with Sporadic Creutzfeldt-Jakob Disease Based on Integrated Bioinformatics Analyses
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Identification of potential key genes and pathway linked with sporadic Creutzfeldt-Jakob disease based on integrated bioinformatics analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.12.21.20248688; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Sporadic Creutzfeldt-Jakob disease (sCJD) is neurodegenerative disease also called prion disease linked with poor prognosis. The aim of the current study was to illuminate the underlying molecular mechanisms of sCJD. The mRNA microarray dataset GSE124571 was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were screened.
    [Show full text]
  • Distinct States of Proinsulin Misfolding in MIDY
    bioRxiv preprint doi: https://doi.org/10.1101/2021.05.10.442447; this version posted May 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Distinct states of proinsulin misfolding in MIDY Leena Haataja1, Anoop Arunagiri1, Anis Hassan1, Kaitlin Regan1, Billy Tsai2, Balamurugan Dhayalan3, Michael A. Weiss3, Ming Liu1,4, and Peter Arvan*1 From: 1The Division of Metabolism, Endocrinology & Diabetes and 2Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor MI 48105; 3Department of Biochemistry and Molecular Biology, Indiana University, Indianapolis, IN 46202; 4Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China *To whom correspondence may be addressed: Peter Arvan MD PhD ORCID ID: http://orcid.org/0000-0002-4007-8799 Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Brehm Tower rm 5112 1000 Wall St. Ann Arbor, MI 48105 email: [email protected] FAX: 734-232-8162 Running Title. Proinsulin Disulfide Mispairing Key Words. endoplasmic reticulum, disulfide bonds, protein trafficking, insulin, diabetes Abbreviations. ER, endoplasmic reticulum; MIDY, Mutant INS-gene induced Diabetes of Youth 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.05.10.442447; this version posted May 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract A precondition for efficient proinsulin export from the endoplasmic reticulum (ER) is that proinsulin meets ER quality control folding requirements, including formation of the Cys(B19)-Cys(A20) “interchain” disulfide bond, facilitating formation of the Cys(B7)-Cys(A7) bridge.
    [Show full text]
  • Proinsulin Levels in Patients with Pancreatic Diabetes Are Associated
    European Journal of Endocrinology (2010) 163 551–558 ISSN 0804-4643 CLINICAL STUDY Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic b-cell area Thomas G K Breuer1, Bjoern A Menge1, Matthias Banasch1, Waldemar Uhl2, Andrea Tannapfel3, Wolfgang E Schmidt1, Michael A Nauck4 and Juris J Meier1 Departments of 1Medicine I and 2Surgery, St Josef-Hospital, Ruhr-University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany, 3Department of Pathology, Ruhr-University Bochum, 44789 Bochum, Germany and 4Diabeteszentrum Bad Lauterberg, 37431 Bad Lauterberg, Germany (Correspondence should be addressed to J J Meier; Email: [email protected]) Abstract Introduction: Hyperproinsulinaemia has been reported in patients with type 2 diabetes. It is unclear whether this is due to an intrinsic defect in b-cell function or secondary to the increased demand on the b-cells. We investigated whether hyperproinsulinaemia is also present in patients with secondary diabetes, and whether proinsulin levels are associated with impaired b-cell area or function. Patients and methods: Thirty-three patients with and without diabetes secondary to pancreatic diseases were studied prior to pancreatic surgery. Intact and total proinsulin levels were compared with the pancreatic b-cell area and measures of insulin secretion and action. Results: Fasting concentrations of total and intact proinsulin were similar in patients with normal, impaired (including two cases of impaired fasting glucose) and diabetic glucose tolerance (PZ0.58 and PZ0.98 respectively). There were no differences in the total proinsulin/insulin or intact proinsulin/insulin ratio between the groups (PZ0.23 and PZ0.71 respectively).
    [Show full text]
  • Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus
    Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (Protocol TN-20) VERSION: January 15, 2016 IND #: 76,419 Sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Allergy and Infectious Diseases (NIAID), the National Center for Research Resources (NCRR), the Juvenile Diabetes Research Foundation International (JDRF), and the American Diabetes Association (ADA) Page 1 of 37 TrialNet Protocol TN20 Protocol Version: 15Jan2016 PREFACE The Type 1 Diabetes TrialNet Protocol TN20, Exploring Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus, describes the background, design, and organization of the study. The protocol will be maintained by the TrialNet Coordinating Center at the University of South Florida over the course of the study through new releases of the entire protocol, or issuance of updates either in the form of revisions of complete chapters or pages thereof, or in the form of supplemental protocol memoranda. Page 2 of 37 TrialNet Protocol TN20 Protocol Version: 15Jan2016 Glossary of Abbreviations AE Adverse event AICD Activation Induced Cell Death APC Antigen presenting cell CBC Complete Blood Count CFR Code of Federal Regulations cGMP Current Good Manufacturing Practice CHO Carbohydrates CRF Case report form DC Dendritic Cell DPT-1 Diabetes Prevention Trial - Type1Diabetes DSMB Data and Safety Monitoring Board ELISPOT Enzyme-Linked ImmunoSpot Assay FACS Fluorescence activated cell sorting FDA US Food
    [Show full text]
  • Recombinant Human Proinsulin Catalog Number: 1336-PN
    Recombinant Human Proinsulin Catalog Number: 1336-PN DESCRIPTION Source E. coli­derived Phe25­Asn110, with an N­terminal Met, 6­His tag and Lys Accession # NP_000198 N­terminal Sequence Met Analysis Predicted Molecular 10.5 kDa Mass SPECIFICATIONS SDS­PAGE 9 kDa, reducing conditions Activity Measured in a serum­free cell proliferation assay using MCF­7 human breast cancer cells. Karey, K.P. et al. (1988) Cancer Research 48:4083. The ED50 for this effect is 0.15­0.75 μg/mL. Endotoxin Level <0.01 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS­PAGE under reducing conditions and visualized by silver stain. Formulation Lyophilized from a 0.2 μm filtered solution in PBS. See Certificate of Analysis for details. PREPARATION AND STORAGE Reconstitution Reconstitute at 100 μg/mL in sterile PBS. Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. Stability & Storage Use a manual defrost freezer and avoid repeated freeze­thaw cycles. l 12 months from date of receipt, ­20 to ­70 °C as supplied. l 1 month, 2 to 8 °C under sterile conditions after reconstitution. l 3 months, ­20 to ­70 °C under sterile conditions after reconstitution. BACKGROUND Proinsulin is synthesized as a single chain, 110 amino acid (aa) preproprecursor that contains a 24 aa signal sequence and an 86 aa proinsulin propeptide. Following removal of the signal peptide, the proinsulin peptide undergoes further proteolysis to generate mature insulin, a 51 aa disulfide­linked dimer that consists of a 30 aa B chain (aa 25 ­ 54) bound to a 21 aa A chain (aa 90 ­ 110).
    [Show full text]
  • Neuroscience Recombinant Proteins & Monoclonal Antibodies
    www.atgenglobal.com Neuroscience Recombinant Proteins & Monoclonal Antibodies Global Bio Frontier Global Bio Frontier Neurodegenerative Disease Neurodegeneration is the progressive loss of Prion disease structure or function of neurons, including death of Frontotemporal dementia Alzheimer's disease neurons. Many neurodegenerative diseases – including amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, and Huntington's disease – occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progres- Lewy body dementia sive degeneration and/or death of neuron cells. As Parkinson's disease research progresses, many similarities appear that relate these diseases to one another on a sub-cellular Huntington's disease level. Neurodegeneration can be found in many different levels of neuronal circuitry ranging from molecular to systemic. Amyotrophic Lateral Sclerosis Related Monoclonal Antibodies Product name Clone No. Applications Host Cat No. AT1E10 ELISA, WB, ICC/IF M ATGA0244 alpha-Synuclein 5C2 ELISA, WB, ICC/IF M ANC0603 alpha/beta-Synuclein 3B6 ELISA, WB, FACS, ICC/IF M ASC0632 HMGB1/HMG-1 J2E1 ELISA, WB, IHC M AHM0915 AT1E12 ELISA, WB, FACS, ICC/IF M ATGA0292 Park7/DJ-1 1B11 ELISA, WB M ADJ0618 UCH-L1/PGP9.5 3D9 ELISA, WB, ICC/IF, IHC M APG0714 AT3F9 ELISA, WB, ICC/IF M ATGA0342 HTRA2/Omi 1B3 ELISA, WB M AOH0607 APP/Protease Nexin II J4H9 ELISA, WB, FACS, ICC/IF M AAP0836 GSK-3 beta 1F7 ELISA, WB, FACS, ICC/IF M AGK0601 SOD1/Cu-Zn SOD AT6F1 ELISA, WB, FACS, ICC/IF M ATGA0405 14-3-3 gamma AT4B9 ELISA, WB, ICC/IF M ATGA0312 14-3-3 epsilon AT4F8 ELISA, WB, ICC/IF M ATGA0124 14-3-3 theta AT1A1 ELISA, WB, ICC/IF M ATGA0132 CAPNS1 AT1D11 ELISA, WB, ICC/IF M ATGA0367 TDP-43/TARDBP k1B8 ELISA, WB, IHC M ATA0834 Alpha-Synuclein antibody (AT1E10) UCH-L1/PGP9.5 antibody (3D9) HMGB1/HMG-1 antibody (J2E1) (Cat No.
    [Show full text]